Medical research

Assessing the impact of fast-track drug approval programs

Over the past decade, regulatory agencies such as the Federal Drug Administration (FDA) in the United States and the and the European Medicines Agency (EMA) in the European Union have put programs in place to get new drugs ...


Biogen pulls controversial Alzheimer's drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.


US makes new Alzheimer's drug more widely accessible

The US drug regulator gave full approval to a new Alzheimer's medicine on Thursday, a move that makes it more widely available to the public through government-run health insurance for the elderly.

page 1 from 2